NCT03821272 2025-10-08
A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients
University of Arkansas
Phase 1/2 Completed
University of Arkansas
National Institutes of Health Clinical Center (CC)
Halozyme Therapeutics
Egetis Therapeutics
Merck KGaA, Darmstadt, Germany
Arya, Vijaypal, M.D., P.C.